We are live on ! Find out more
ACET icon

Adicet Bio
ACET

41 hedge funds and large institutions have $100M invested in Adicet Bio in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

3% more funds holding

Funds holding: 40 → 41 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more ownership

Funds ownership: 0.37% → 0.37% (+0%)

33% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 15

43% less capital invested

Capital invested by funds: $177M → $100M (-$76.9M)

Holders
41
Holders Change
+1
Holders Change %
+2.5%
% of All Funds
0.91%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
10
Reduced
15
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$3.91M
2
SCM
Segantii Capital Management
Hong Kong
+$3.08M
3
OAM
Oxford Asset Management
United Kingdom
+$270K
4
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
+$262K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$183K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$3.52M
2
DAM
Deltec Asset Management
New York
-$1.71M
3
AG
Artal Group
Luxembourg
-$1.18M
4
AA
ALPS Advisors
Colorado
-$751K
5
Goldman Sachs
Goldman Sachs
New York
-$647K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIG
26
American International Group
New York
$44K -$1.32K -1 -2%
Wells Fargo
27
Wells Fargo
California
$30K +$26.3K +20 +182%
UBS Group
28
UBS Group
Switzerland
$23K +$3.95K +3 +14%
MWNA
29
Marshall Wace North America
New York
$19K +$26.3K +20 New
SO
30
STRS Ohio
Ohio
$16K – – –
TRCT
31
Tower Research Capital (TRC)
New York
$12K -$10.5K -8 -40%
Citigroup
32
Citigroup
New York
$12K -$7.9K -6 -32%
Bessemer Group
33
Bessemer Group
New Jersey
$12K – – –
Legal & General Group
34
Legal & General Group
United Kingdom
$10K – – –
Barclays
35
Barclays
United Kingdom
$6K -$39.5K -30 -83%
AIP
36
Ameritas Investment Partners
Nebraska
$5K – – –
PNC Financial Services Group
37
PNC Financial Services Group
Pennsylvania
$2K – – –
Royal Bank of Canada
38
Royal Bank of Canada
Ontario, Canada
$1K -$1.32K -1 -50%
Bank of Montreal
39
Bank of Montreal
Ontario, Canada
$1K +$1.32K +1 New
Schroder Investment Management Group
40
Schroder Investment Management Group
United Kingdom
$884 +$262K +199 +28%
BNP Paribas Financial Markets
41
BNP Paribas Financial Markets
France
$793 -$1.32K -1 -50%
Millennium Management
42
Millennium Management
New York
– -$3.52M -2,076 Closed
AA
43
ALPS Advisors
Colorado
– -$751K -443 Closed
VEA
44
Virtus ETF Advisers
New York
– -$642K -379 Closed
Retirement Systems of Alabama
45
Retirement Systems of Alabama
Alabama
– -$91K -54 Closed
1
2

ACET Hedge Fund Activity: Q4 2018 in Review

41 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q4 2018, worth a combined $100M — down 43% from $177M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ACET positions and 4 closed out — a net gain of 1 holder — while 10 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $3.91M. The largest seller was Millennium Management, exiting entirely with an estimated $3.52M sold.

  • 41 institutional investors held Adicet Bio (ACET) as of Q4 2018, up from 40 in Q3 2018.
  • Funds reported $100M of Adicet Bio stock for Q4 2018, down 43% quarter-over-quarter.
  • 5 funds opened new Adicet Bio positions in Q4 2018 and 4 closed out, a net change of +1 holder.
  • The largest Adicet Bio buyer in Q4 2018 was BlackRock, an estimated $3.91M added.
  • The largest Adicet Bio seller in Q4 2018 was Millennium Management, an estimated $3.52M sold.

Based on aggregated 13F filings for Q4 2018.